Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 9/20 | 0.50 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.50 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.41 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | MGLL | Q99685 | 2/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.36 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.36 |
| ▸ | LIPE | Q05469 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL580859 | 0.89 | FFAR4 (0.47) | FFAR4NOTUMHSD11B1PDE4APDE4B | |
| Hydrochloric Acid SCHEMBL581934 | 0.85 | FFAR4 (0.40) | FFAR4NOTUMHSD11B1PDE4APDE4B | |
| SCHEMBL582163 | 0.83 | NOTUM (0.46) | FFAR4NOTUMHSD11B1 | |
| SCHEMBL3086468 | 0.82 | NOTUM (0.42) | NOTUMHSD11B1DPP4DPP8DPP7 | |
| SCHEMBL587408 | 0.81 | FFAR4 (0.40) | FFAR4NOTUMHSD11B1CHRM4MGLL | |
| SCHEMBL581486 | 0.80 | FFAR4 (0.40) | FFAR4NOTUMHSD11B1CHRM4ENPP2 | |
| SCHEMBL582014 | 0.80 | NOTUM (0.43) | NOTUMHSD11B1MGLLDPP4 | |
| SCHEMBL581391 | 0.78 | PLG (0.38) | FFAR4NOTUMCHRM4 | |
| SCHEMBL3075498 | 0.78 | NOTUM (0.37) | NOTUMDPP4DPP8DPP7 | |
| SCHEMBL582008 | 0.75 | POLB (0.42) | FFAR4NOTUMHSD11B1CHRM4ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8415378-B2 | Isoxazol-3(2H)-one analogs as therapeutic agents | ASTRAZENECA AB (SE) | 2013-04-09 | — | — | US | disclosed |
| EP-2417131-A1 | ISOXAZOL-3(2H)-ONE ANALOGS AS THERAPEUTIC AGENTS | AstraZeneca AB (SE) | 2012-02-15 | — | — | EP | disclosed |
| WO-2010117323-A1 | METHOD AND APPARATUS FOR PRODUCING HEAT ENERGY AND CARBON DIOXIDE | ASTRAZENECA AB (SE) | 2010-10-14 | — | — | WO | disclosed |
| US-20100261755-A1 | ISOXAZOL-3(2H)-ONE ANALOGS AS THERAPEUTIC AGENTS | ASTRAZENECA AB (SE) | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261755-A1 | ISOXAZOL-3(2H)-ONE ANALOGS AS THERAPEUTIC AGENTS | NR4A3, CBR3, OXER1 | FFAR4 10/4885NOTUM 2559/4885HSD11B1 1197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.